Project Grant R42AI155312

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $847,141 to investigate the non-catalytic function of HIV-1 integrase (IN) during virion morphogenesis and to continue research on the antiviral mechanism of a promising investigational drug, pirmitegravir (PIR), that targets IN-viral RNA interactions. The research aims to delineate the structural features of viral RNA...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $859,992 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to Yale University to conduct research into the molecular mechanisms underlying HIV-1 maturation and the impact of inhibitors on this process. The research is structured around two specific aims: 1) Determining the high-resolution structural pathway of HIV-1 Gag assemblies and capsid during maturation within their native cellular...

This $223,300 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to develop novel HIV capsid-targeting antivirals that can maintain activity against lenacapavir-resistant HIV viruses. The primary award recipient, Emory University, is conducting studies to synthesize and characterize analogs of a lead compound that can bind the HIV capsid more effectively in...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $1,314,572 to Yale University to develop and translate small-molecule CD4-mimetic compounds (CD4MCs) as a cure strategy for HIV-1. The project aims to investigate physiological variables that facilitate effective reservoir elimination using CD4MC/antibody (CD4MC/AB) interventions in humanized mouse models, formulate a...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $617,376.00 to Emory University to conduct research on understanding the timing and regulation of HIV-1 protease autoactivation and virus maturation. The key products and services to be delivered include: Implementing and validating specialized imaging approaches using FRET probes to visualize single HIV-1...

This Project Grant award of $687,416 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to develop therapeutics that can block and lock HIV reactivation in people living with both HIV and substance use disorders (SUD). The key objectives are to: 1) Determine how CDK9 inhibitors and PP2A activators can block and lock HIV reactivation, especially in the context of addictive substances; 2) Develop a targeted small...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $1,420,190 to the University of California, Davis to understand the reservoir effects and curative potential of a CD3/CCR5 bispecific antibody in infant macaques. The key objectives are to: 1) test the safety and CCR5 depletion effects of the bispecific antibody produced using different manufacturing methods, 2)...

This $564,001 project grant from the National Institutes of Health's National Institute of Allergy and Infectious Diseases will fund research on membrane-associated RING CH (MARCH) proteins and their role in restricting HIV-1 infection. MARCH proteins are a family of ubiquitin ligases that regulate membrane receptors and have been shown to restrict HIV-1 and other retroviruses by blocking viral envelope incorporation into budding virions. The research foundation for the State University of New...

This federal Project Grant award, with ID R61AI188553, was provided by the National Institute of Child Health and Human Development under the Child Health and Human Development Extramural Research program (CFDA 93.865). The $2,207,322 award will fund the development of ultra-long-acting prodrug formulations for antiretroviral therapy (ART) targeted at improving treatment outcomes for pediatric populations living with HIV-1 infection. The key products and services to be delivered include...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $2,688,880.00 to Emory University to evaluate the safety and therapeutic potential of a novel strategy to achieve sustained HIV remission. The key products and services to be delivered under this award include: Conducting comprehensive studies to assess how a combination therapy of IL-15/IL-15RA and TGF-beta pathway...